advanced pca; transdermal e2; side-effects

* In patients with locally advanced prostate cancer, tE2 was noninferior to LHRH agonists for 3-year metastasis-free survival, with a lower incidence of hot flashes but a higher incidence of gynecomastia. https://www.nejm.org/doi/full/10.1056/NEJMoa2511781?query=featured_home Abstract...